



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Atty. Docket No: ETH5231USPCT

In re patent application of

TROTTER, PATRICK et al.

Serial No. 10/529,157

Filed: March 24, 2005

For: ENZYME-SENSITIVE THERAPEUTIC WOUND DRESSINGS

STATEMENT TO SUPPORT FILING AND SUBMISSION IN  
ACCORDANCE WITH 37 C.F.R. §§ 1.821-1.825

Commissioner for Patents  
P.O. Box 1450  
Alexandria, Virginia 22313-1450  
Mail Stop SEQUENCE

Sir:

In connection with a Sequence Listing submitted concurrently herewith, the undersigned hereby states that:

1. the submission, filed herewith in accordance with 37 C.F.R. § 1.821(g), does not include new matter;

2. the content of the attached paper copy and the attached computer readable copy of the Sequence Listing, submitted in accordance with 37 C.F.R. § 1.821(c) and (e), respectively, are the same.

Respectfully submitted,

March 24, 2006  
Date

James A. Coburn  
James A. Coburn

HARBOR CONSULTING IP SERVICES, INC.  
1500A Lafayette Road, #262  
Portsmouth, N.H. 03801  
800-318-3021

## STIC Biotechnology Systems Branch

*PU*

### CRF Problem Report

The Biotechnology Systems Branch of the Scientific and Technical Information Center (STIC) experienced a problem when processing the following computer readable form (CRF):

Application Serial Number: 10/529,157A  
Filing Date: 3/24/05  
Date Processed by STIC: 2/6/06

STIC Contact: Mark Spencer: Telephone: 571-272-2510; Fax: 571-273-0221

#### Nature of CRF Problem:

- ☐ (circle one) Damaged or Unreadable (for Unreadable, see attached)  
☐ Blank (no files on CRF) (see attached)  
☐ Empty file (filename present, but no bytes in file) (see attached)  
☐ Wrong file saved to CRF (invention title, docket number, or applicant(s) do not match those in official application) (see attached)  
☒ Not saved in ASCII text (*see attached*)  
☐ Sequence Listing was embedded in the file. According to Sequence Rules, submitted file should **only** be the Sequence Listing.  
☐ Did not contain a Sequence Listing. (see attached sample)  
☐ Other:

**PLEASE USE THE CHECKER VERSION 4.4.0 PROGRAM TO REDUCE ERRORS.  
SEE BELOW FOR ADDRESS:**

<http://www.uspto.gov/web/offices/pac/checker/chkrnote.htm>

1. EFS-Bio (<http://www.uspto.gov/ebs/efs/downloads/documents.htm>) , EFS Submission User Manual - ePAVE)
2. U.S. Postal Service: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450
3. Hand Carry, Federal Express, United Parcel Service, or other delivery service (EFFECTIVE 01/14/05):  
U.S. Patent and Trademark Office, Mail Stop Sequence, Customer Window, Randolph Building, 401 Dulany Street, Alexandria, VA 22314

Revised 01/20/06

## Raw Sequence Listing Error Summary

**ERROR DETECTED****SUGGESTED CORRECTION**SERIAL NUMBER: 10/529,157A

ATTN: NEW RULES CASES: PLEASE DISREGARD ENGLISH "ALPHA" HEADERS, WHICH WERE INSERTED BY PTO SOFTWARE

- 1      Wrapped Nucleics  
    Wrapped Aminos    The number/text at the end of each line "wrapped" down to the next line. This may occur if your file was retrieved in a word processor after creating it. Please adjust your right margin to .3; this will prevent "wrapping."
- 2      Invalid Line Length    The rules require that a line not exceed 72 characters in length. This includes white spaces.
- 3      Misaligned Amino  
    Numbering    The numbering under each 5<sup>th</sup> amino acid is misaligned. Do not use tab codes between numbers; use space characters, instead.
- 4      Non-ASCII    The submitted file was not saved in ASCII(DOS) text, as required by the Sequence Rules. Please ensure your subsequent submission is saved in ASCII text.
- 5      Variable Length    Sequence(s)      contain n's or Xaa's representing more than one residue. Per Sequence Rules, each n or Xaa can only represent a single residue. Please present the maximum number of each residue having variable length and indicate in the <220>-<223> section that some may be missing.
- 6      PatentIn 2.0  
    "bug"    A "bug" in PatentIn version 2.0 has caused the <220>-<223> section to be missing from amino acid sequences(s)     . Normally, PatentIn would automatically generate this section from the previously coded nucleic acid sequence. Please manually copy the relevant <220>-<223> section to the subsequent amino acid sequence. This applies to the mandatory <220>-<223> sections for Artificial or Unknown sequences.
- 7      Skipped Sequences  
    (OLD RULES)    Sequence(s)      missing. If intentional, please insert the following lines for each skipped sequence:  
                          (2) INFORMATION FOR SEQ ID NO:X: (insert SEQ ID NO where "X" is shown)  
                          (i) SEQUENCE CHARACTERISTICS: (Do not insert any subheadings under this heading)  
                          (xi) SEQUENCE DESCRIPTION:SEQ ID NO:X: (insert SEQ ID NO where "X" is shown)  
                          This sequence is intentionally skipped  
  
                          Please also adjust the "(ii) NUMBER OF SEQUENCES:" response to include the skipped sequences.
- 8      Skipped Sequences  
    (NEW RULES)    Sequence(s)      missing. If intentional, please insert the following lines for each skipped sequence.  
                          <210> sequence id number  
                          <400> sequence id number  
                          000
- 9      Use of n's or Xaa's  
    (NEW RULES)    Use of n's and/or Xaa's have been detected in the Sequence Listing.  
                          Per 1.823 of Sequence Rules, use of <220>-<223> is MANDATORY if n's or Xaa's are present.  
                          In <220> to <223> section, please explain location of n or Xaa, and which residue n or Xaa represents.
- 10      Invalid <213>  
    Response    Per 1.823 of Sequence Rules, the only valid <213> responses are: Unknown, Artificial Sequence, or scientific name (Genus/species). <220>-<223> section is required when <213> response is Unknown or is Artificial Sequence
- 11      Use of <220>    Sequence(s)      missing the <220> "Feature" and associated numeric identifiers and responses.  
                          Use of <220> to <223> is MANDATORY if <213> "Organism" response is "Artificial Sequence" or "Unknown." Please explain source of genetic material in <220> to <223> section.  
                          (See "Federal Register," 06/01/1998, Vol. 63, No. 104, pp. 29631-32) (Sec. 1.823 of Sequence Rules)
- 12      PatentIn 2.0  
    "bug"    Please do not use "Copy to Disk" function of PatentIn version 2.0. This causes a corrupted file, resulting in missing mandatory numeric identifiers and responses (as indicated on raw sequence listing). Instead, please use "File Manager" or any other manual means to copy file to floppy disk.
- 13      Misuse of n/Xaa    "n" can only represent a single nucleotide; "Xaa" can only represent a single amino acid

These  
are  
prior  
data  
↓

# SEQUENCE LISTING

1

10/529, 157A

<110> JOHNSON & JOHNSON MEDICAL LIMITED  
<120> ENZYME-SENSITIVE THERAPEUTIC WOUND DRESSING  
<130> P031972WO

<1507> ~~<140>~~ PCT/GB03/04250  
<1517> ~~<141>~~ 2003-10-01

<150> GB 0222722.1  
<151> 2002-10-01

<160> 23

<170> SeqWin99, version 1.02

<210> 1

<211> 6

<212> PRT

<213> Artificial Sequence

<220>

<223> Oligopeptide sequence cleavable by elastase

<400> 1

Lys Gly Ala Ala Ala Lys  
1 5

<210> 2

<211> 4

<212> PRT

<213> Artificial Sequence

<220>

<223> Oligopeptide sequence cleavable by elastase

<400> 2

Ala Ala Pro Val  
1

<210> 3

<211> 4

<212> PRT

<213> Artificial Sequence

<220>

<223> Oligopeptide sequence cleavable by elastase

<400> 3

Ala Ala Pro Leu  
1

<210> 4

<211> 4

<212> PRT

<213> Artificial Sequence

<220>

<223> Oligopeptide sequence cleavable by elastase

Same  
error as  
previous  
submission;

what is  
the source  
of genetic  
material?

see item 11 on  
Error summary  
sheet.

same error

File was saved  
in "pdf" format,  
which is invalid,  
per Sequence Rules.  
File MUST be  
saved in ASCII  
text format.

10/529/57A

<400> 4  
Ala Ala Pro Phe  
1

<210> 5  
<211> 4  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Oligopeptide sequence cleavable by elastase

<400> 5  
Ala Ala Pro Ala  
1

<210> 6  
<211> 4  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Oligopeptide sequence cleavable by elastase

<400> 6  
Ala Tyr Leu Val  
1

<210> 7  
<211> 6  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Oligopeptide sequence cleavable by a matrix metalloprotease

<400> 7  
Gly Pro Xaa Gly Pro Xaa  
1 5

<210> 8  
<211> 6  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Oligopeptide sequence cleavable by a matrix metalloprotease

<400> 8  
Gly Pro Leu Gly Pro Xaa  
1 5

<210> 9  
<211> 6  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Oligopeptide sequence cleavable by a matrix metalloprotease

*Explain Xaas in 2207-2237  
section  
(see item 9  
on Ena  
summary  
sheet)*

10/529,157A

<400> 9  
Gly Pro Ile Gly Pro Xaa  
1 5

<210> 10  
<211> 5  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Oligopeptide sequence cleavable by a matrix metalloprotease

<400> 10  
Ala Pro Gly Leu Xaa  
1 5

<210> 11  
<211> 7  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Oligopeptide sequence cleavable by collagenase

<400> 11  
Pro Leu Gly Pro Asp Arg Xaa  
1 5

<210> 12  
<211> 7  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Oligopeptide sequence cleavable by collagenase

<400> 12  
Pro Leu Gly Leu Leu Gly Xaa  
1 5

<210> 13  
<211> 7  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Oligopeptide sequence cleavable by collagenase

<400> 13  
Pro Gln Gly Ile Ala Gly Trp  
1 5

<210> 14  
<211> 5  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Oligopeptide sequence cleavable by collagenase

<220>

<221> MOD\_RES  
<222> Cysteine residue  
<223> Methylation

<400> 14  
Pro Leu Gly Cys His  
1 5

<210> 15  
<211> 6  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Oligopeptide sequence cleavable by collagenase

<400> 15  
Pro Leu Gly Leu Trp Ala  
1 5

<210> 16  
<211> 7  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Oligopeptide sequence cleavable by collagenase

<400> 16  
Pro Leu Ala Leu Trp Ala Arg  
1 5

<210> 17  
<211> 7  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Oligopeptide sequence cleavable by collagenase

<400> 17  
Pro Leu Ala Tyr Trp Ala Arg  
1 5

<210> 18  
<211> 7  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Oligopeptide sequence cleavable by gelatinase

<400> 18  
Pro Leu Gly Met Trp Ser Arg  
1 5

<210> 19  
<211> 4  
<212> PRT  
<213> Artificial Sequence

10/529, 157A  
Insert "4" <sup>series</sup> Cys is at location 4  
put this on <2237> line.  
<2227> line is used  
for location of a  
modified residue

Where is  
remainder of sequence listing?

10/529,157A

**P031972WO Sequences for Listing:**

Lys-Gly-Ala-Ala-Ala-Lys  
Ala-Ala-Pro-Val  
Ala-Ala-Pro-Leu  
Ala-Ala-Pro-Phe  
Ala-Ala-Pro-Ala  
Ala-Tyr-Leu-Val

Gly-Pro-Y-Gly-Pro-Z  
Gly-Pro-Leu-Gly-Pro-Z  
Gly-Pro-Ile-Gly-Pro-Z  
Ala-Pro-Gly-Leu-Z

Pro-Leu-Gly-Pro-D-Arg-Z  
Pro-Leu-Gly-Leu-Leu-Gly-Z  
Pro-Gln-Gly-Ile-Ala-Gly-Trp  
Pro-Leu-Gly-Cys(Me)-His  
Pro-Leu-Gly-Leu-Trp-Ala  
Pro-Leu-Ala-Leu-Trp-Ala-Arg  
Pro-Leu-Ala-Tyr-Trp-Ala-Arg

Pro-Leu-Gly-Met-Trp-Ser-Arg

Gly-Arg-Gly-Asp  
Gly-Arg-Gly-Asp-Asn-Pro  
Gly-Arg-Gly-Asp-Ser  
Gly-Arg-Gly-Asp-Ser-Pro-Lys

Pro-Tyr-Ala-Tyr-Trp-Met-Arg

**TOTAL : 23 SEQUENCES**

**All artificial sequences.**

**Three a/a sequences ignored.**

Assume D = Asn (see page 9, line 2).

What is  
this?

These  
are  
not  
in  
valid  
format  
for  
a  
sequence  
listing